Thromboembolic And Bleeding Risks During anticoaGulant trEatment in Asian paTients With Atrial Fibrillation (TARGET-AF) (NOAC)

Chung-Ang University Hosptial, Chung-Ang University College of Medicine

Status: Invitation-only

Conditions: Fibrillation, Atrial

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT06874894

CAUH 1992-002-387

Details and patient eligibility

About

This study was design to investigate the efficacy and safety of NOAC therapy in Koreans

Full description

East Asians have demonstrated a higher bleeding tendency compared to Western populations during an anticoagulation. Consequently, East Asians have been prescribed as a relatively weaker treatment regimens based on this evidence. Therefore, the TARGET-AF study aims to verify the efficacy and safety of NOAC therapy using biomarkers including TEG®-6S point-of-care device in Koreans

Enrollment: 1,021 estimated patients

Sex: All

Ages: 18+ months old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with documented AF on 12-lead ECG, Holter monitoring, or single-lead ECG recordings are eligible for enrollment.
• Based on AF treatment Korean guideline 19, AF patients who require NOAC treatment or are currently on NOAC treatment (within the past 3 months)
• Adults aged 18 or above who have provided consent for clinical information

Exclusion criteria

• Patients with moderate or severe mitral stenosis or mechanical prosthetic valve

Trial design

1,021 participants in 1 patient group

Atrial Fibrillation

Description:

Documented AF on 12-lead ECG, Holter monitoring, or single-lead ECG recordings and biomarkers using TEG®-6S with NOAC treatment